Abstract
Despite biomarker-guided treatment strategies, clinical outcomes among patients with type 2 (T2)-high asthma remain heterogeneous, with some patients responding poorly to T2-targeted biologic therapies. We developed a contrastive machine learning method for patient stratification based on whole-blood DNA methylation (DNAm), applying it to pediatric asthma cohorts of Latino (discovery; n=1,016) and African American (replication; n=429) children. The resulting DNAm stratification score revealed a continuum of clinical severity and drug response within the T2-high asthma endotype. Molecular profiling of high-score asthma patients identified eosinophil-specific hypermethylation—validated in an independent Canadian adult cohort using purified eosinophil DNAm—as well as upregulation of canonical T2-associated genes. Transcriptomic analysis of elevated DNAm scores within T2-high patients further uncovered a gene signature linked to B-cell lineage activity, predominantly reflecting plasma cell activity orthogonal to canonical T2 inflammation programs. This defines a previously unrecognized sub-endotype, which we term T2-high asthma with Altered B Cell response (T2ABC). In a randomized controlled trial of the anti-IgE biologic omalizumab in primarily White adult T2-high asthmatic patients (n=300), the T2ABC gene expression signature was prognostic of poor outcomes, including a 24% mean increase in disease exacerbation rates compared to the trial baseline (P=0.004), which could not be explained by treatment or placebo assignment. Patients treated with omalizumab showed better outcomes than patients in the placebo arm within the T2ABC-low group (P=0.019) but not within the T2ABC-high group (P=0.48), suggesting that IgE blockade does not adequately target the pathogenic mechanisms active in T2ABC-high disease. Single-cell transcriptomic analysis demonstrated that the T2ABC signature reflects heightened activity of non-IgE plasma cells, consistent with the presence of additional antibody isotype responses in a form of severe asthma arising within a T2-high immunologic context. Our findings, replicated and validated across four ancestrally and ethnically diverse pediatric and adult cohorts, support the use of DNAm- and transcriptome-based patient stratification to refine drug development, eligibility, and administration strategies for improving precision in T2 asthma therapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A.G., E.R. and J.F. were supported, in part, by the National Institute of Mental Health grant R01MH122569. E.R. was supported by the National Human Genome Research Institute grant 1R21HG013393. A.G and J.F were also supported, in part, by the National Institute of Mental Health grant R01MH130581. J.P.G. was supported by fellowship FPU19/02175 (Formacion de Profesorado Universitario Program) from the Spanish Ministry of Science, Innovation, and Universities (MICIU). This work was supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the American Lung Association [CAALA2023], the National Institutes of Health, National Heart, Lung, and Blood Institute [Grants 1K23HL169911, R01HL155024-01, R01HL117004, R01HL128439, R01HL135156, X01HL134589], the National Institute of Health and Environmental Health Sciences [R01ES015794, R21ES24844], the National Institute on Minority Health and Health Disparities [R01MD010443, R56MD013312], and the Tobacco-Related Disease Research Program [24RT-0025, 27IR-0030]. This research was also supported by the UK Biobank Resource under application 33127.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols for both GALA II and SAGE were approved by the University of California, San Francisco (UCSF) Human Research Protection Program Institutional Review Board (#10-0889 and #10-08277) and each institution participating in recruitment obtained the appropriate approval from its respective institutional review board (IRB): Kaiser Permanente Northern California IRB (#CN-07EBrig and #CN-05HFarb), Children's Memorial Hospital IRB (#2008-13531), Children's Hospital & Research Center Oakland IRB (#2009-017), Albert Einstein College of Medicine IRB (#2005-032), Northwestern University IRB (#CR1_STU00008687), IRB for Baylor College of Medicine and Affiliated Hospitals (#H-22861), San Juan VA Medical Center Institutional Review Board, and Western IRB, Inc. (#1073894).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data produced in the present study will be made available after formal peer-review publication
